Four finalist teams have been chosen!
They will pitch their final solutions to a panel of expert judges on June 8. Following pitch sessions, one winner will receive $20,000 toward the development of their solution, a one-year membership at MATTER and a pilot opportunity with Roche Diabetes Care. Read more about the finalists below.
It's time to act.
EVERY 7 SECONDS, a person dies from diabetes and its complications.
BY 2045, more than 629 million people are expected to have diabetes — an increase of more than 50 percent.
Roche Diabetes Care has spent 40+ YEARS pioneering innovative diabetes technologies and services.
EVERY SECOND, more than 200 tests are performed with an Accu-Chek blood glucose monitoring system.
A person living with diabetes today faces numerous complex healthcare decisions that affect both their near-term and long-term health. They and their healthcare providers are navigating through a maze of multiple therapeutic interventions, a wide variety of diet and nutrition options and a plethora of exercise regimens — all of which affect blood sugar control. Despite all of these options, people with diabetes are often still at a loss to understand how these activities work together to improve their diabetes management by easily translating the volume of data available to them into meaningful insights that can help drive care.
It’s time to empower people living with diabetes. Roche Diabetes Care has partnered with MATTER to explore, source and pilot digital and device-enabled solutions or services that address one or a combination of the priority areas listed below:
How might we help people with diabetes more precisely identify the right combinations of therapies, diet, exercise and other behaviors that will improve their blood glucose control?
How might we help people living with diabetes optimize these interventions through improved monitoring and tracking that enhance control over their diabetes management?
How might we equip people with diabetes and their healthcare providers with actionable insights and intelligence that help them implement a targeted and personalized roadmap of care?
VIDEO: Learn more about the unique needs of people with diabetes.
- Two to five finalists will receive a $5,000 cash award to further develop their solutions
- The winning finalist will receive a monetary prize of $20,000 from Roche Diabetes Care, to be used for further development of the finalist’s entry and associated solution(s)
- Further mentoring and education in the field of diabetes and diabetic patients from selected and trained Roche Diabetes Care leaders, MATTER staff and stakeholders from across the healthcare community
- A free 1-year membership at MATTER
- JAN 17: Submission deadline
- JAN 22: Semifinalists announced
- FEB 2 - FEB 7: Bootcamp at MATTER
- MAR 30: Semifinalist pitch day, finalists announced
- JUN 8: Final pitch day
This challenge is open to startups that have an established business model, ideally have some evidence about product-market fit and are seeking opportunities to pilot their solutions within health systems. If actively fundraising, Roche Diabetes Care will accept submissions from companies pursuing a seed, Series A or Series B round.
Read the Roche Diabetes Care Innovation Contest FAQs for more information.
Click here to submit your application between November 20, 2019 at 2:00pm CST and January 17, 2020 at 11:59pm CST.
10 to 15 selected semi-finalists will be notified via the email indicated in their application by January 22. Semi-finalists will be invited to participate in a required incubation period, including a five-day bootcamp at MATTER in Chicago, IL in February 2020. During the incubation period, finalists will refine their value proposition and perfect their pitch. Finalist teams are strongly encouraged to take advantage of MATTER workshops and mentor hours during incubation.
The incubation period will culminate in a pitch day at MATTER on February 26, 2020, where semi-finalists will present their solutions to Roche executives and the MATTER community. Following the event, two to five finalists will progress to the accelerator phase.
The accelerator runs from March 2 to May 5, 2020 and will culminate in a final presentation on May 7 that details a pilot opportunity with Roche.
Questions? Email email@example.com
About Roche Diabetes Care
Roche Diabetes Care is pioneering innovative diabetes technologies and services for more than 40 years. Being a global leader in integrated Personalised Diabetes Management, more than 5,000 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target range and experience true relief from the daily therapy routines.
Roche Diabetes Care collaborates with caregivers, healthcare providers and payers to optimally manage this complex condition and contribute to sustainable care structures. Under the brand Accu-Chek and in collaboration with partners, Roche Diabetes Care creates value by providing integrated solutions to monitor glucose levels, deliver insulin and track as well as contextualize relevant data points for a successful therapy. By establishing a leading open ecosystem, connecting devices and digital solutions, Roche Diabetes Care will enable optimal personalized diabetes management and thus improve therapy outcomes.
Since 2017, mySugr with its world-leading mobile diabetes management app and services is part of Roche Diabetes Care. For more information, please visit www.accu-chek.com and www.mysugr.com.
All trademarks used or mentioned in this release are protected by law.
At MATTER, we believe collaboration is the best way to improve healthcare. The MATTER collaborative includes more than 200 cutting-edge startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.
 Source: 1 IDF Diabetes Atlas 8th ed., International Diabetes Federation, 2017